文献速递糖尿病

胰高血糖素受体拮抗剂RVT-1502在二甲双胍单药控制不佳的2型糖尿病中的疗效与安全性:12周剂量范围研究

Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study.
PubMed 文献 · Diabetes Care · 2019-11-06

这项2期双盲随机安慰剂对照研究纳入166例二甲双胍稳定剂量下控制不佳的2型糖尿病患者,随机接受安慰剂或RVT-1502 5、10、15 mg每日一次治疗12周。结果显示RVT-1502各剂量较安慰剂显著降低HbA1c和空腹血糖,低血糖频率低且无严重事件,安全性支持进一步长疗程临床开发。

要点

  • RVT-1502 5、10、15 mg较安慰剂显著降低HbA1c达0.74%、0.76%、1.05%(P<0.001)。
  • 空腹血糖较安慰剂降低2.1、2.2、2.6 mmol/L(P<0.001)。
  • 低血糖频率低且无严重事件,转氨酶轻度可逆升高但未超正常上限。

核心结论

  • 胰高血糖素受体拮抗剂RVT-1502可显著降低二甲双胍控制不佳2型糖尿病患者的HbA1c和空腹血糖,安全性支持进一步长疗程研究。

研究设计与样本

  • 2期双盲随机安慰剂对照研究,纳入166例二甲双胍稳定剂量下控制不佳的2型糖尿病患者,按1:1:1:1随机接受安慰剂或RVT-1502 5、10、15 mg每日一次治疗12周。

主要发现

  • 12周时RVT-1502 5、10、15 mg组HbA1c较安慰剂分别降低0.74%、0.76%、1.05%(P<0.001)。
  • 空腹血糖较安慰剂分别降低2.1、2.2、2.6 mmol/L(P<0.001)。
  • HbA1c<7.0%达标率在安慰剂及RVT-1502 5、10、15 mg组分别为19.5%、39.5%、39.5%、45.0%(vs安慰剂P≤0.02)。
  • 低血糖频率低且无严重事件;RVT-1502组转氨酶均值轻度升高但低于正常上限,可逆且似与剂量无关,其他肝参数无变化。
  • 体重和血脂变化在RVT-1502与安慰剂间相似;RVT-1502相关血压轻度升高与剂量无关且随时间不一致。

临床怎么用

  • RVT-1502作为新型口服胰高血糖素受体拮抗剂,在二甲双胍单药控制不佳的2型糖尿病患者中显示出降HbA1c和空腹血糖的疗效,且低血糖风险低,但需关注转氨酶和血压的轻度变化。

局限性

  • 研究为12周短期剂量范围研究,样本量166例,长期疗效与安全性需更长疗程研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evaluate the safety and efficacy of RVT-1502, a novel oral glucagon receptor antagonist, in subjects with type 2 diabetes inadequately controlled on metformin. RESEARCH DESIGN AND METHODS: In a phase 2, double-blind, randomized, placebo-controlled study, subjects with type 2 diabetes (n = 166) on a stable dose of metformin were randomized (1:1:1:1) to placebo or RVT-1502 5, 10, or 15 mg once daily for 12 weeks. The primary end point was change from baseline in HbA1c for each dose of RVT-1502 compared with placebo. Secondary end points included change from baseline in fasting plasma glucose (FPG) and safety assessments. RESULTS: Over 12 weeks, RVT-1502 significantly reduced HbA1c relative to placebo by 0.74%, 0.76%, and 1.05% in the 5-, 10-, and 15-mg groups (P < 0.001), respectively, and FPG decreased by 2.1, 2.2, and 2.6 mmol/L (P < 0.001). The proportions of subjects achieving an HbA1c <7.0% were 19.5%, 39.5%, 39.5%, and 45.0% with placebo and RVT-1502 5, 10, and 15 mg (P ≤ 0.02 vs. placebo). The frequency of hypoglycemia was low, and no episodes were severe. Mild increases in mean aminotransferase levels remaining below the upper limit of normal were observed with RVT-1502 but were reversible and did not appear to be dose related, with no other liver parameter changes. Weight and lipid changes were similar between RVT-1502 and placebo. RVT-1502-associated mild increases in blood pressure were not dose related or consistent across time. CONCLUSIONS: Glucagon receptor antagonism with RVT-1502 significantly lowers HbA1c and FPG, with a safety profile that supports further clinical development with longer-duration studies (NCT02851849).

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Pettus JH, D'Alessio D, Frias JP, et al. Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study. Diabetes Care. 2019. PMID: 31694861. doi:10.2337/dc19-1328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。